The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. حسب Gui Araujo (22170819)

"…Parameter values: interaction strengths were drawn from a half-normal distribution of zero mean and a standard deviation of 0.2, and strength for consumers was made no larger than the strength for resources. …"

Loss of ECRG4 expression decreases neutrophil mobilization from bone marrow reserves. حسب Katie D. Pool (20141584)

الموضوعات:

Mean values and 95% confidence intervals for recovery time, Average NN Interval (AVNN); Standard Deviation of NN Intervals (SDNN), Low Frequency/ High Frequency Ratio (LF/HF); and... حسب Robert Trybulski (10998702)

Youthful systemic milieu in young recipients decreased apoptosis and oxidative stress damage in allografts, and promoted proliferation. حسب Chengjun Yu (12136227)

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. حسب Yue Chen (73753)

Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest. حسب Helal El-Zaatari (20442243)

"…<p>Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest.…"

Root-mean-square fluctuation (RMSF) analysis of wild-type and p.R163C mutant αB-crystallin dimers from molecular dynamics simulations. حسب Aref Baharvand (21713886)

Force analysis of the system. حسب Jianbo Jia (717814)

الموضوعات:

Loss of MAP4K4 expression causes a decrease in the number of neutrophils. حسب Guihua Wang (286390)

MYCN overexpression leads to decreased <i>id2a</i> expression in early SCG. حسب Rodrigo Ibarra-García-Padilla (19697623)

The working principle of the Welleader system. حسب Jianbo Jia (717814)

الموضوعات:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Long-term anti-nucleocapsid response by baseline patient characteristics. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Baseline patient characteristics across neutralizing monoclonal antibody trials. حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... حسب Elizabeth S. Munroe (21568166)

الموضوعات:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). حسب Elizabeth S. Munroe (21568166)

الموضوعات: